Top Players - Crohn's Disease Treatment Industry

The market for treating Crohn's disease is anticipated to expand rapidly as a result of factors such the rise in inflammatory bowel disorders (IBD) and the number of people with the condition. For example, a disease-death model based on available data was constructed to forecast the future incidence of IBD in Asia, and Iran in particular, from 2017 to 2035, according to a study published in the Journal BMC Gastroenterology in May 2021. According to the finding, the study anticipated a 2.5 fold increase in prevalence for Iran with 69 thousand situations in 2035 especially in contrast to a 2022, a 2.3 fold growth for North Africa and the Middle East with 2.2 million cases, a 1.5 fold enhanced for East Asia region with 4.5 million cases and a 1.6 fold keep increasing for greater Asia-Pacific and Southeast Asia region with 183 and 199 thousand cases, including both.

Global Crohn’s Disease Treatment Market is estimated to be valued at US$ 10.92 billion in 2022 and is expected to exhibit a CAGR of 4.2% during the forecast period (2022-2030)

Leading Companies in the Crohn's Disease Treatment Industry:

1.  AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide since 2012. It is headquartered in North Chicago and operational in more than 70 countries. AbbVie and HotSpot Therapeutics, Inc., in December, 2022 announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases.

2.  Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products globally from 1887. The company was headquartered in New York, New York. In September, 2022 announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu™ (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Sotyktu is not recommended for use in combination with other potent immunosuppressants.

3. Boehringer Ingelheim GmbH

Founded in 1885 leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. In June, 2022

Boehringer Ingelheim launches Fencovis®, a new vaccine to prevent calf diarrhea.

4. Pfizer Inc.

Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sell biopharmaceutical products worldwide. In December, 2022 announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age.

5. Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.  Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly and Company and EVA Pharma announced in December, 2022 a collaboration to deliver a sustainable supply of high-quality, affordable human and analogue insulin to at least one million people living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are in Africa.

6. Novartis AG

The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide.  Novartis in December, 2022 announced the European Commission (EC) approved Pluvicto^® (INN: lutetium (¹⁷⁷Lu) vipivotide tetraxetan), a targeted radioligand therapy.

7. Sanofi

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions and was founded in 1973. The company is headquartered in Paris, France and is operational in 100 plus countries. Sanofi and Innate Pharma SA announced in December, 2022 an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform.

8. Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. Taked, Zedira and Dr. Falk Pharma GmbH in October, 2022 announced a collaboration and licensing agreement to develop ZED1227/TAK-227, a Phase 2b investigational therapy for the treatment of celiac disease.

9. AstraZeneca. 

AstraZeneca PLC was incorporated in 1992.The company is headquartered in Cambridge, the United Kingdom and operational in more than 100 countries. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. In December, 2022 AstraZeneca’s Calquence (acalabrutinib), a selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naïve chronic lymphocytic leukaemia (CLL)

*Definition-

Crohn’s disease is a form of inflammatory bowel disease (IBD) that refers to a chronic inflammatory condition of the gastrointestinal tract causing inflammation in the digestive tract.